Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.
Blagden SP. et al, (2023), Br J Cancer, 128, 474 - 477
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Jones R. et al, (2023), Clin Cancer Res, 29, 331 - 340
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis EJ. et al, (2022), J Immunother Cancer, 10
A qualitative exploration of digital medicines information usage: Insights from an evaluation of the BNF
Blagden S. et al, (2022), Health Policy and Technology, 11
Interventions delivered in secondary or tertiary medical care settings to improve routine vaccination uptake in children and young people: a scoping review.
Blagden S. et al, (2022), BMJ Open, 12
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR. et al, (2022), Lancet Oncol, 23, 919 - 930
PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
Nicum S. and Blagden SP., (2022), Clin Cancer Res, 28, 2201 - 2203
Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.
Pantziarka P. and Blagden S., (2022), Cancers (Basel), 14
Targeting MAPK in recurrent, low-grade serous ovarian cancer.
Blagden SP., (2022), Lancet, 399, 499 - 501
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial.
Schwenzer H. et al, (2021), Clin Cancer Res, 27, 6500 - 6513
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Kazmi F. et al, (2021), Cochrane Database of Systematic Reviews, 2021
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
Frangou E. et al, (2021), Gynecol Oncol, 162, 431 - 439
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.
Kazmi F. et al, (2021), Clin Cancer Res, 27, 3028 - 3038
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells
Masuda K. et al, (2021), JCI Insight
NICE public health guidance update.
Blagden S. et al, (2021), J Public Health (Oxf), 43, e107 - e109